Anders Lundin

Anders Lundin is an experienced financial consultant with a diverse background in interim CFO and financial advisory roles across various companies in the biotechnology and pharmaceutical sectors. Since August 2024, Anders has served as an Interim Financial Consultant at Bifrost Biosystems, while concurrently holding positions as a Board Member at EMPE Diagnostics and Interim CFO at Airsonett AB via Proxecutive. Previous experience includes roles as Interim Senior Financial Advisor at PeptiSystems AB and Immuneed, and as Interim CFO and Investor Relations at Q-linea, leading a successful IPO on Nasdaq Stockholm. Anders also held interim CFO positions at Medivir AB, BioPhausia AB, and Oasmia Pharmaceutical AB, focusing on IPO preparations and compliance with financial reporting standards. Academic qualifications include a Bachelor of Business Administration from Uppsala University and an Executive Education degree in Management and Corporate Governance.